Goldman Sachs is a global financial services firm that provides investment banking, securities, and investment management services to corporations, governments, financial institutions, and high-net-worth individuals. It advises on mergers and acquisitions, restructurings, and other corporate actions; underwrites public offerings and debt; and helps clients raise capital through various markets. The firm engages in market making and client execution across fixed income, currencies, commodities, and equities, and offers securities services including financing and lending to institutional clients. Its asset management and wealth advisory businesses manage assets and provide investment solutions for a broad client base, including institutions and individuals. Headquartered in New York, the company serves clients worldwide and operates across multiple business lines to support capital formation, risk management, and investment activities.
Managing Director and Head of Alternative Energy Investing
Philip Aldis
Partner
Andre Alfaro
Managing Director
Margaret Anadu
Managing Director
Sara Beth Beckmeier
Vice President
Past deals in Nanotechnology
Attovia Therapeutics
Series C in 2025
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Attovia Therapeutics
Series B in 2024
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
MoMa Therapeutics
Series B in 2022
Founded in 2019 and based in Cambridge, Massachusetts, MoMa Therapeutics discovers precision medicines by targeting molecular machines underlying human diseases. The company's platform enables drug development from previously intractable enzyme classes.
Invarium
Series B in 2006
Invarium, Inc. is a company based in San Jose, California, that specializes in providing advanced patterning synthesis solutions for the semiconductor industry. Established in 2003, Invarium focuses on enhancing pattern accuracy on silicon for integrated circuit (IC) designs, particularly for sub-90-nanometer technologies. The company's flagship product, DimensionPPC, accelerates time-to-volume production, thereby assisting IC designers and manufacturers in achieving improved layout printability. Invarium operates as a subsidiary of Cadence Design Systems, Inc., further extending its capabilities and reach within the semiconductor sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.